Literature DB >> 19963130

Fluorescence in situ hybridization analysis using PAX8- and PPARG-specific probes reveals the presence of PAX8-PPARG translocation and 3p25 aneusomy in follicular thyroid neoplasms.

Wai Kit Chia1, Noor Akmal Sharifah, Rahayu Md Zin Reena, Zakaria Zubaidah, Ching Huat Clarence-Ko, Muhammad Rohaizak, Ibrahim Naqiyah, Das Srijit, Abdullah Nor Hisham, Arbi Asmiati, Md Kaslan Rafie.   

Abstract

At the present time, the differentiation between follicular thyroid carcinoma (FTC) and adenoma can be made only postoperatively and is based on the presence of capsular or vascular invasion. The ability to differentiate preoperatively between the malignant and benign forms of follicular thyroid tumors assumes greater importance in any clinical setting. The PAX8-PPARG translocation has been reported to occur in the majority of FTC. In this study, a group of 60 follicular thyroid neoplasms [18 FTC, 1 Hurthle cell carcinoma (HCC), 24 follicular thyroid adenomas (FTA), 5 Hurthle cell adenomas (HCA), and 12 follicular variants of papillary thyroid carcinomas (FV-PTC)] were analyzed to determine the prevalence of the PAX8-PPARG translocation by fluorescence in situ hybridization. The PAX8-PPARG translocation was detected in 2/18 FTC (11.1%). In addition, 2/18 (11.1%) FTC and 1/5 (20%) HCA showed 3p25 aneusomy only. The frequency of the translocation detected in the study was lower compared to the earlier studies conducted in Western countries. This might be attributed to the ethnic background and geographic location. Detection of either the PAX8-PPARG translocation or the 3p25 aneusomy in FTC indicates that these are independent genetic events. It is hereby concluded that 3p25 aneusomy or PAX8-PPARG translocation may play an important role in the molecular pathogenesis of follicular thyroid tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19963130     DOI: 10.1016/j.cancergencyto.2009.08.001

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Identification of novel Pax8 targets in FRTL-5 thyroid cells by gene silencing and expression microarray analysis.

Authors:  Tina Di Palma; Anna Conti; Tiziana de Cristofaro; Serena Scala; Lucio Nitsch; Mariastella Zannini
Journal:  PLoS One       Date:  2011-09-23       Impact factor: 3.240

2.  Development of an RNA sequencing panel to detect gene fusions in thyroid cancer.

Authors:  Dongmoung Kim; Seung-Hyun Jung; Yeun-Jun Chung
Journal:  Genomics Inform       Date:  2021-12-31

Review 3.  Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome.

Authors:  Myriem Boufraqech; Naris Nilubol
Journal:  Cancers (Basel)       Date:  2019-12-10       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.